Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) provides today an overview of data presented during the 51st Annual Meeting of the American Society of Hematology (“ASH”), taking place on December 5-8, 2009 in New Orleans, LA, with notably updated Phase II interim data with IPH 1101 in non-Hodgkin’s lymphoma, as well as an update on IHP 2101 Phase I trials.
Poster #1649, presented by Guy Laurent, MD (Hemato-Oncology department, CHU Purpan, Toulouse, France), co-lead investigator of the trial, notably reports updated interim clinical data with IPH 1101 in combination with rituximab (Mabthera/Rituxan®) in non-Hodgkin’s lymphoma patients. On the first 34 evaluable patients assessed by independent central review, 16 patients showed a response (i.e. 47% Overall Response Rate, or “ORR”), including 11 patients showing a complete response (i.e. 32% Complete Response Rate or “CRR”). The complete response rate observed with standard of care (rituximab alone) in similar settings is 11% CRR [1]. Final data on all evaluable patients are expected by mid-2010. Poster detailing these results can be downloaded on Innate Pharma’s website (www.innate-pharma.com).
